Login to Your Account



Synergy shares rise on positive CIC drug data

By Michael Fitzhugh
Staff Writer

Wednesday, June 17, 2015
Synergy Pharmaceuticals Inc. shares (NASDAQ:SGYP) leapt 67.7 percent to close at $7.78 Wednesday on news that the company's wholly owned chronic idiopathic constipation (CIC) drug, plecanatide, met the primary endpoint in the first of two pivotal phase III studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription